Home › Leucemia acuta bifenotipica › Tennessee
Studi clinici su Leucemia acuta bifenotipica nello stato di Tennessee
10 studi su Leucemia acuta bifenotipica cercano partecipanti presso sedi nello stato di Tennessee.
Città nello stato di Tennessee
Testo ufficiale dello studio (inglese)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- East Tennessee Childrens Hospital, Knoxville
- Saint Jude Children's Research Hospital, Memphis
- The Children's Hospital at TriStar Centennial, Nashville
- e altri 1
In reclutamentoFase 2
365 Days · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06317662Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- T C Thompson Children's Hospital, Chattanooga
- East Tennessee Childrens Hospital, Knoxville
- The Children's Hospital at TriStar Centennial, Nashville
- e altri 1
In reclutamentoFase 3
365 Days – 25 Years · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- East Tennessee Childrens Hospital, Knoxville
- Saint Jude Children's Research Hospital, Memphis
- The Children's Hospital at TriStar Centennial, Nashville
- e altri 1
In reclutamentoFase 1/2
Fino a 22 anni · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT04726241Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- St. Jude Children's Research Hospital, Memphis
In reclutamentoFase 2
Età da 1 a 18 · Tutti i sessi · Aggiornato il 10 ago 2026 · NCT06390319Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
In reclutamentoFase 1/2
Età da 13 a 90 · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT06533579Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- St. Jude Children's Research Hospital, Memphis
In reclutamentoFase 1
Età da 1 a 30 · Tutti i sessi · Aggiornato il 3 ago 2026 · NCT06177067Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
- St. Jude Children's Research Hospital, Memphis
In reclutamentoFase 4
Età da 1 a 18 · Tutti i sessi · Aggiornato il 14 lug 2026 · NCT06289673Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Vanderbilt University, Ingram Cancer Center, Nashville
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 lug 2026 · NCT07216443The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Baptist Clinical Research Institute, Memphis
In reclutamentoFase 1/2
Età da 12 a 95 · Tutti i sessi · Aggiornato il 15 apr 2026 · NCT04329728Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- St. Jude Children's Research Hospital, Memphis
In reclutamentoFase 1
Età da 1 a 21 · Tutti i sessi · Aggiornato il 6 dic 2024 · NCT05476770Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.